Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The Company's lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). The Company is conducting a Phase Ib/IIa trial for PF582 in patients with wet age-related macular degeneration (wet AMD). The Company's next most advanced product candidate is PF530, a biosimilar candidate to Betaseron (interferon beta-1b). The Company's pipeline includes five other preclinical biosimilar products under development, such as PF726, PF529, PF688, PF694 and PF444. It is also developing a vaccine Px563L, which is an anthrax vaccine candidate; a generic product PF708, and next generation biologic candidates. The Company's product candidates are enabled by its patented protein production platform, Pfenex Expression Technology.
News 
Market Data 
Discover 
